近期,诺瓦瓦克斯医药(NVAX)股价在盘中出现大幅上涨,报收7.04%。此次股价大涨,或与公司推出的一种新型疫苗的临床试验结果有关。
诺瓦瓦克斯医药是一家专注于新型疫苗开发的生物技术公司。公司最近公布的财报显示,其营收和利润水平虽然不佳,但在新型疫苗的研发方面取得了突破性进展。行业分析人士表示,如果诺瓦瓦克斯的新型疫苗通过审批并成功上市,将帮助公司大幅改善财务状况,被市场看好。
另一方面,机构分析师对该股持看多态度。在参与评级的6家机构中,有50%给予"买入"评级,反映出外界对公司前景的期望。不过也有部分机构保持了审慎态度,给予"卖出"或"持有"评级。总的来说,这一利好临床进展消息,以及良好的外界评级推动了股价的大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.